Table 2.
scFv | VH | VL | REF. | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
CDR2 | CDR3 | FW1 | FW3 | CDR3 | ||||||||
C1 | 54 S |
56 D |
57 N |
105 M |
107 A |
110 Y |
164 S |
204 A |
208 D |
235 L |
236 I |
[25] |
RU1 | G | G | L | H | [23] | |||||||
ER-1 | G | G | S | L | T | I | G | [22] | ||||
10F | G | G | S | L | T | I | G | T | L | α | ||
10F1 | G | G | S | L | T | I | G | G | T | L | α | |
10F2 | G | G | S | L | N | G | G | T | L | α | ||
10F3 | G | G | S | L | N | G | T | L | α | |||
10F4 | G | G | S | L | S | N | G | G | T | L | α | |
10F5 | G | G | S | L | S | T | G | G | T | L | α | |
10F6 | G | G | S | L | S | N | G | T | L | α |
α ER-1 variants generated in this work; mutation positions are shown. VH corresponds to the variable domain of antibody heavy chain and VL is the corresponding variable domain of a light chain. CDR stands for complementarity-determining region and FW means framework. scFvs indicated in bold correspond to variants derived from scFv 10F.